Inhibitors of histone acetyltransferases (HATs, also known as lysine acetyltransferases), such as CBP/p300, are potential therapeutics for treating cancer. However, rigorous methods for validating these inhibitors are needed. Three in vitro methods for validation include HAT assays with recombinant acetyltransferases, immunoblotting for histone acetylation in cell culture, and ChIP-qPCR.
Lysine acetyltransferases (KATs) catalyze acetylation of lysine residues on histones and other proteins to regulate chromatin dynamics and gene expression. KATs, such as CBP/p300, are under intense investigation as therapeutic targets due to their critical role in tumorigenesis of diverse cancers. The development of novel small molecule inhibitors targeting the histone acetyltransferase (HAT) function of KATs is challenging and requires robust assays that can validate the specificity and potency of potential inhibitors.
This article outlines a pipeline of three methods that provide rigorous in vitro validation for novel HAT inhibitors (HATi). These methods include a test tube HAT assay, Chromatin Hyperacetylation Inhibition (ChHAI) assay, and Chromatin Immunoprecipitation-quantitative PCR (ChIP-qPCR). In the HAT assay, recombinant HATs are incubated with histones in a test tube reaction, allowing for acetylation of specific lysine residues on the histone tails. This reaction can be blocked by a HATi and the relative levels of site-specific histone acetylation can be measured via immunoblotting. Inhibitors identified in the HAT assay need to be confirmed in the cellular environment.
The ChHAI assay uses immunoblotting to screen for novel HATi that attenuate the robust hyperacetylation of histones induced by a histone deacetylase inhibitor (HDACi). The addition of an HDACi is helpful because basal levels of histone acetylation can be difficult to detect via immunoblotting.
The HAT and ChHAI assays measure global changes in histone acetylation, but do not provide information regarding acetylation at specific genomic regions. Therefore, ChIP-qPCR is used to investigate the effects of HATi on histone acetylation levels at gene regulatory elements. This is accomplished through selective immunoprecipitation of histone-DNA complexes and analysis of the purified DNA through qPCR. Together, these three assays allow for the careful validation of the specificity, potency, and mechanism of action of novel HATi.
Lysine acetyltransferases (KATs) catalyze the acetylation of lysine residues on both histone and non-histone proteins1,2,3,4. Recent research reveals that KATs and their acetyltransferase function can promote solid tumor growth4,5,6,7,8,9. For example, CREB-binding protein (CBP)/p300 are two paralogous KATs that regulate numerous signaling pathways in cancer2,3. CBP/p300 have a well characterized histone acetyltransferase (HAT) function and catalyze Histone 3 Lysine 27 acetylation (H3K27ac)2,4,5,10,11, an important marker for active enhancers, promoter regions and active gene transcription12,13,14. CBP/p300 serve as critical co-activators for pro-growth signaling pathways in solid tumors by activating transcription of oncogenes through acetylation of histones and other transcription factors4,9,15,16,17,18. Due to their role in tumor progression, CBP/p300 and other KATs are under investigation for the development of novel inhibitors that block their oncogenic function4,5,6,7,8,9,18,19,20. A-485 and GNE-049 represent two successful attempts to develop potent and specific inhibitors for CBP/p3004,9. Additional inhibitors are currently under investigation for CBP/p300 and other KATs.
The quality of previously described KAT inhibitors (KATi) is being called into question, with many inhibitors showing off target effects and poor characterization21. Therefore, rigorous characterization and validation of novel drug candidates is essential for the development of high-quality chemical probes. Outlined here are three protocols that form a pipeline for screening and rigorously validating the potency and specificity of novel KATi, with a specific focus on inhibiting the HAT function (HATi) of KATs. CBP/p300 and their inhibitors are used as examples, but these protocols can be adapted for other KATs that have a HAT function7.
The first protocol is an in vitro histone acetyltransferase (HAT) assay that utilizes purified recombinant p300 and histones in a controlled test tube reaction. This assay is simple to perform, is cost-effective, can be used to screen compounds in a low throughput setting, and does not require radioactive materials. In this protocol, recombinant p300 catalyzes lysine acetylation on histone tails during a brief incubation period and the levels of histone acetylation are measured using standard immunoblotting procedures. The enzymatic reaction can be performed in the presence or absence of CBP/p300 inhibitors to screen for compounds that reduce histone acetylation. Additionally, the HAT assay can be used to verify whether novel compounds are selective for CBP/p300 by assessing their activity against other purified KATs, such as PCAF. The HAT assay is an excellent starting point for investigating novel inhibitors due to its simplicity, low cost, and the ability to determine the potency/selectivity of an inhibitor. Indeed, this protocol is often used in the literature as an in vitro screen5,10. However, inhibitors identified in the HAT assay are not always effective in cell culture because a test tube reaction is much simpler than a living cell system. Therefore, it is essential to further characterize inhibitors in cell culture experiments22,23.
The second protocol in the pipeline is the Chromatin Hyperacetylation Inhibition (ChHAI) assay. This cell based assay utilizes histone deacetylase inhibitors (HDACi) as a tool to hyperacetylate histones in chromatin before co-incubation with a HATi24. Basal histone acetylation can be low in cell culture, making it difficult to probe for via immunoblotting without the addition of an HDACi to increase acetylation. The purpose of the ChHAI assay is to identify novel HATi that can attenuate the increase in histone acetylation caused by HDAC inhibition. The advantages of this assay include its low cost, relative ease to perform, and the use of cells in culture, which provides more physiological relevance than the test tube HAT assay. Similar to the HAT assay, this protocol uses standard immunoblotting for data collection.
The HAT and ChHAI assays provide data about the potency of novel compounds for inhibiting global histone acetylation, but do not provide insight into how these compounds affect modifications at specific genomic regions. Therefore, the final protocol, Chromatin Immunoprecipitation-quantitative Polymerase Chain Reaction (ChIP-qPCR) is a cell culture experiment that investigates DNA-protein interactions at specific regions of the genome. In the ChIP protocol, chromatin is crosslinked to preserve DNA-protein interactions. The chromatin is then extracted from cells and the DNA-protein complex undergoes selective immunoprecipitation for the protein of interest (e.g., using an antibody specific for H3K27ac). The DNA is then purified and analyzed using qPCR. For example, ChIP-qPCR can be used to determine if a novel HATi downregulates histone acetylation at individual oncogenes, such as Cyclin D125. While ChIP-qPCR is a common technique used in the field, it can be difficult to optimize4,10,26. This protocol provides tips for avoiding potential pitfalls that can occur while performing the ChIP-qPCR procedure and includes quality control checks that should be performed on the data.
When used together, these three protocols allow for the rigorous characterization and validation of novel HATi. Additionally, these methods offer many advantages because they are easy to perform, relatively cheap and provide data on global as well as regional histone acetylation.
1. In vitro HAT assay
2. ChHAI assay
3. ChIP-qPCR
NOTE: The protocol below is described for inhibitors of p300 as an example.
The in vitro histone acetyltransferase (HAT) assay can be used to probe for compounds that inhibit p300 HAT activity towards a histone substrate. Figure 1A provides an experimental schematic for the HAT assay. Anacardic acid, a known HATi3,38, was utilized in this assay in a concentration range from 12.5-100 µM. At 100 µM, anacardic acid downregulates p300 catalyzed histone acetylation at Histone 3, Lysines 9 and 18 versus the control DMSO treatment (Figure 1B, lane 5 versus lane 1). A concentration range was utilized in this assay because lower drug dosages may not greatly inhibit p300 HAT activity (Figure 1B, lanes 2-4 versus lane 1). In Lane 6, no Acetyl-CoA was added to the reaction and serves as a negative control for p300 catalysis and for basal levels of histone acetylation on recombinant H3.1 (Figure 1B). p300 and H3.1 protein levels were utilized as loading controls (Figure 1B). These immunoblot results were quantified using ImageJ39 (Figure 1C). Fold changes were calculated by comparing the band intensity of each sample to the band intensity of the DMSO control for each acetylation probe. Quantification for anacardic acid at 100 µM shows potent reduction in H3K18ac and H3K9ac versus the DMSO control, confirming the visual results in Figure 1B.
In the Chromatin Hyperacetylation Inhibition (ChHAI) assay, HDACi is used as a tool to hyperacetylate histones in chromatin before co-incubation with a HATi24, such as p300 inhibitor A-4852,4. The purpose of this assay is to determine the efficacy of HATi for attenuating histone hyperacetylation induced by HDACi. Figure 2A provides an experimental schematic for the ChHAI assay. In this assay, treatment of MCF-7 cells with HDACi MS-275 strongly upregulated acetylation on Histone 3, on several lysine residues (Figure 2B, lane 4 versus lane 1). The basal levels of H3K18ac and H3K27ac were low, showing the benefits of adding an HDACi in the ChHAI assay (Figure 2B, lanes 1-3). The addition of A-485 with MS-275 attenuates the increased histone acetylation at H3K18 and H3K27, but not H3K9 (Figure 2B, lanes 4-6). Importantly, H3K9ac is not regulated by p300 in cell culture2, showing the specificity of A-485 in this experiment. These immunoblot results were quantified in Figure 2C. Fold changes were calculated by comparing the band intensity of each sample to the band intensity of MS-275 alone (Lane 4) for each acetylation probe. Lanes 1-3 were not quantified because H3K18ac and H3K27ac basal levels were not detected.
Chromatin Immunoprecipitation-quantitative Polymerase Chain Reaction (ChIP-qPCR) is a cell culture experiment that investigates DNA-protein interactions at specific regions of the genome. It can be used to investigate the effects of HATi at gene regulatory elements that control oncogene expression25. Figure 3A provides an experimental schematic for the ChIP-qPCR protocol. MCF-7 cells treated with 3 µM A-485 for 24 hours were subjected to ChIP-qPCR through immunoprecipitation of histone-DNA complexes enriched in H3K27ac (Figure 3). The purified DNA was analyzed for the Cyclin D1 promoter sequence. ChIP-qPCR primers are designed against a specific DNA sequence in the genome and are used to detect the relative amount of precipitated DNA. The amount of precipitated DNA reflects the abundance of the protein of interest at the genomic region under investigation. Indeed, in the DMSO sample, the DNA precipitated by the IgG control antibody produces a higher Ct value than the H3K27ac antibody in the qPCR reaction for the Cyclin D1 promoter (Figure 3B). This indicates that the non-specific IgG control precipitated less DNA-protein complexes than the H3K27ac specific antibody at the Cyclin D1 promoter. This translates to a 632.73 fold enrichment of H3K27ac over the non-specific IgG control (Figure 3B).
This fold enrichment provides evidence that the H3K27ac specific antibody successfully immunoprecipitated acetylated histones and that H3K27ac is enriched at the Cyclin D1 promoter. After validating the quality of the H3K27ac antibody, a comparison can be made between the DMSO and A-485 treated groups. As shown in Figure 3C, A-485 reduces H3K27ac enrichment at the Cyclin D1 promoter versus the DMSO control using the %Input method (representative result of n=2). Importantly, A-485 is known to significantly reduce H3K27ac in cell culture2,4.
ChIP-qPCR raw %Input values can be highly variable between independent biological replicates, despite the experimental trend being reproducible. Therefore, it may be useful to present the data as a normalized percent of DMSO control to show the reproducible ratio between control and drug treatment10. For example, in Figure 3D, A-485 significantly downregulates H3K27ac occupancy at the Cyclin D1 promoter (n=2). Statistical analysis was based on the Student’s t-test (*P < 0.05).
Figure 1: Anacardic acid inhibits p300 enzymatic activity in a HAT assay. (A) A schematic diagram of the HAT assay, depicting the enzymatic reaction. (B) Anacardic acid potently inhibited p300 enzymatic activity and downregulated histone acetylation at H3K18 and H3K9 at 100 μM (lane 5) versus the DMSO control treatment (lane 1). Lane 6 lacks Acetyl-CoA in the reaction and served as a negative control for histone acetylation. (C) The immunoblot results in (B) were quantified. Fold changes were calculated by comparing the band intensity of each sample to the band intensity of the DMSO control for each acetylation probe. Please click here to view a larger version of this figure.
Figure 2: p300 inhibitor A-485 potently attenuates histone hyperacetylation in the ChHAI assay. (A) A schematic diagram of the ChHAI assay. (B) In MCF-7 cells, HDAC inhibitor MS-275 potently upregulated histone acetylation at H3K18, K27 and K9 (lane 4) versus the DMSO control (lane 1). The addition of A-485, a known p300 HAT inhibitor, with MS-275 attenuated the increase in histone acetylation at H3K18 and K27, but not H3K9 (lanes 5-6 versus lane 4). (C) The immunoblot results in (B) were quantified. Fold changes were calculated by comparing the band intensity of each sample to the band intensity of MS-275 alone (Lane 4) for each acetylation probe. Lanes 1-3 were not quantified because H3K18ac and H3K27ac basal levels were not detected. Please click here to view a larger version of this figure.
Figure 3: p300 inhibitor A-485 decreases H3K27ac levels at the Cyclin D1 promoter as measured by ChIP-qPCR. (A) A schematic diagram of the ChIP-qPCR protocol. (B) Representative qPCR Ct values for the Cyclin D1 promoter for the IgG and H3K27ac immunoprecipitations. The IgG control had a higher Ct value, indicating that the H3K27ac antibody successfully enriched for H3K27ac over the non-specific IgG antibody. (C) A-485 (3 μM) treatment for 24 h downregulated H3K27ac at the Cyclin D1 promoter in comparison to the DMSO control treatment in MCF-7 cells (representative result of n=2). (D) The %Input from two independent ChIP experiments were normalized to the DMSO control as a percentage of the DMSO control. Treatment with A-485 in MCF-7 cells significantly downregulates H3K27ac occupancy at the Cyclin D1 promoter. Statistical analysis was based on the Student’s t-test (*P < 0.05). Please click here to view a larger version of this figure.
Buffer | Recipe | |
10X Glycine buffer | 18.74 g of glycine with PBS until dissolved and add PBS to 200 ml. | |
10X Running Buffer | 250 mM Tris, 1.9 M glycine, 1% SDS Dissolve 30.0 g of Tris base, 144.0 g of glycine, and 10.0 g of SDS in 1000 ml of H2O. The pH of the buffer should be 8.3 and no pH adjustment is required. Store the running buffer at room temperature and dilute to 1X before use. |
|
10X TBST | 2.42 g of Tris base, 8g of NaCl, 2 ml of 50% Tween 20, add ddH2O to 1 liter | |
1X TBST with 5% milk | 5g powdered milk per approximate 100 ml of 1X TBST | |
5X Assay buffer: | 500 mM HEPES, pH 7.5, 0.4 % Triton X-100 | |
5X Passive lysis buffer | make an aqueous stock containing 125 mM Tris, pH 7.8, 10 mM 1,2-CDTA, 10 mM DTT, 5 mg/ml BSA, 5% (vol/vol) Triton X-100 and 50% (vol/vol) glycerol in ddH2O. | |
6X Sodium Dodecyl Sulfate (SDS) | 0.375 M Tris pH 6.8, 6 ml glycerol, 1.2 g SDS, 0.93 g 1,4-dithiothreitol (DTT), 6 mg bromophenol blue, add water to 10 ml. | |
ChIP dilution buffer | 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM Tris-HCl pH 8.0, 167 mM NaCl | |
ChIP Elution Buffer | 1% SDS (w/v) and 0.1 M NaHCO3 in autoclaved ddH2O | |
Complete DMEM for MCF-7 Cells: | Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% bovine calf serum (BCS), penicillin (10 units/ml), and streptomycin (10 mg/ml) | |
High salt wash buffer | 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 200 mM Tris-HCl pH 8.0, 500 mM NaCl. | |
LiCl wash buffer | 0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 100 mM Tris-HCl pH 8.0. | |
Low salt wash buffer | 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 200 mM Tris-HCl pH 8.0, 150 mM NaCl. | |
Nuclei swelling buffer | 5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40 | |
SDS lysis buffer | 1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0 | |
TE buffer | 10 mM Tris-HCl pH 8.0, 1 mM EDTA. | |
Transfer buffer | 25 mM Tris, 190 mM glycine, 20% methanol and check the pH and adjust to pH 8.3 if necessary. |
Table 1: Recipes of the buffers and solution used.
Supplementary files: Supplementary experimental schematics for Protocols 1-3. Please click here to download this file.
Lysine acetyltransferases (KATs) acetylate several lysine residues on histone tails and transcription factors to regulate gene transcription2,3. Work in the last two decades has revealed that KATs, such as CBP/p300, PCAF and GCN5, interact with oncogenic transcription factors and help drive tumor growth in several solid tumor types4,5,9,15,16,17,18. Due to their emerging role in promoting tumor growth, KATs are being investigated as novel targets in cancer treatment. Novel KAT inhibitors (KATi) need to be carefully and rigorously tested for potency, selectivity, and safety before moving to use in the clinic. Recent evidence has shown that previously described KATi compounds exhibit off target effects and were poorly characterized before being widely used in the scientific literature as chemical probes21. Therefore, rigorous methods are needed for KATi characterization. Described here are three protocols that can be used together to characterize and validate novel inhibitors targeting the histone acetyltransferase (HAT) function of KATs: an in vitro HAT assay, the ChHAI assay, and ChIP-qPCR. These protocols use CBP/p300 and their inhibitors as examples, but these methods can easily be adapted for future application in investigating other KATs.
The HAT assay is simple and a cost-effective way to screen compounds for potency in inhibiting HAT function in a test tube. Purified HATs (either recombinant4,10 or immunoprecipitated40) can be tested in this assay, but recombinant CBP/p300 is used as an example in this protocol. CBP/p300 have an enzymatic HAT domain that transfers an acetyl group from Acetyl-CoA to a lysine residue on a target substrate3. The most characterized CBP/p300 histone targets are Histone 3 Lysine 18 and 27 (H3K18 and H3K27, respectively)2,3,10,11. In the HAT assay, the purified p300 HAT domain is incubated with Acetyl-CoA and Histone 3.1 as a substrate. During the incubation period, p300 will catalyze acetylation on several H3.1 residues including H3K18 and H3K27. The relative abundance of acetylation on these residues can be measured via immunoblotting. This test tube reaction can be used to screen for novel compounds that bind to p300 and inhibit its HAT activity (HATi). For example, anacardic acid, a known HATi38, potently downregulates histone acetylation at both H3K18 and H3K9 in comparison to the DMSO control (Figure 1B, lane 5 versus lane 1). It is critically important to add Acetyl-CoA to the experimental reactions (Figure 1B, Lanes 1-5) or p300 catalysis of histone acetylation will not occur (Figure 1B, Lane 6). The absence of Acetyl-CoA can also be used as a negative control for p300 catalysis and for basal levels of histone acetylation on recombinant H3.1.
When performing the HAT assay, it is important to ensure that each reaction receives the same amount of p300, H3.1 and Acetyl-CoA. H3.1 and p300 levels in the immunoblot serve as loading controls for the gel. For this assay, site-specific histone acetyl antibodies or a pan-acetyl antibody can be used for immunoblotting. When optimizing to improve immunoblot quality it is crucial to use validated antibodies for immunoblotting and to initially follow the manufacturer’s recommendations for antibody dilution. The antibody dilutions used in the Protocol section are for reference and the dilutions can be changed based on the results of initial experiments (e.g., if the signal is too strong the antibody can be further diluted). Due to its simplicity, the HAT assay is an excellent starting experiment for screening novel inhibitors. However, the HAT assay does have disadvantages. A major concern with the HAT assay is that compounds that are effective in a test tube may prove ineffective in a living system. This is an issue because compound efficacy in cell culture can be altered by cellular permeability issues, cellular metabolism, and compound stability. In addition, KATs, specifically CBP/p300, have many protein-protein interactions that regulate their KAT activity in cell culture3,41,42. Therefore, it is essential to further characterize inhibitors identified in the HAT assay in cell culture experiments20,23.
The Chromatin Hyperacetylation Inhibition (ChHAI) assay is the second protocol in the pipeline and is useful for validating the effects of novel inhibitors in cell culture. This assay utilizes HDAC inhibitors (HDACi)24 to induce histone hyperacetylation in cells because basal acetylation can be too low to detect on an immunoblot. The cell lines of choice are pre-incubated with an HDACi to allow for accumulation of acetylated chromatin before the addition of a HATi. After co-incubating the HDACi and HATi, the cells are lysed and subjected to standard immunoblotting procedures for specific histone acetylation sites. The purpose of this assay is to determine the efficacy of novel HATi for attenuating histone hyperacetylation induced by HDACi. Cells exposed to HDACi should have significantly higher levels of histone acetylation than cells exposed to the DMSO solvent (Figure 2B, lane 4 versus lane 1). Addition of the HATi along with the HDACi is expected to reduce the immunoblot signal in comparison to the HDACi treatment alone (Figure 2B, lanes 5-6 versus lane 4). Basal levels of histone acetylation (Figure 2B, Lanes 1-3) are difficult to detect and highlights the importance of adding an HDACi in this protocol. MS-275 (Entinostat) is used as an example but other HDACi can be used24,43. MS-275 has variable reported inhibitory concentrations versus Class I HDACs and generally inhibits HDAC1 and HDAC3 with nanomolar to low micromolar concentrations, respectively43,44. A wide range of MS-275 concentrations is used in the literature45,46,47, but a 3 µM treatment provides a robust and reproducible increase in histone acetylation in MCF-7 cells. Therefore, it may be beneficial to perform an initial screen with a wide range of HDACi and HATi concentrations to determine the optimal concentration for the ChHAI assay when using a different cell line.
Similar to the HAT assay, the immunoblot protocol may need to be optimized to obtain quality results through the use of appropriate antibodies, optimal antibody dilutions and carefully controlled sample loading. Carefully controlled sample loading is essential for the success of this protocol and can be achieved through equilibrating the protein content of all samples and through pipetting equal volume of samples into the wells of the immunoblot gel. A pan-acetyl antibody can be used for probing in this protocol. However, it should be supplemented with site-specific acetyl antibodies because KATs have specificity for certain histone lysine residues and HATi does not affect all histone acetylation sites in cell culture1,2,4,5,10,11. Inhibitors that are potent at reducing histone acetylation in both the HAT and ChHAI assays are strong candidates for further evaluation. Importantly, the HAT and ChHAI assays have the limitation of only providing data about global changes in histone acetylation. This limitation creates the need to characterize the effects of novel HATi at specific regions of the genome.
Chromatin Immunoprecipitation-quantitative Polymerase Chain Reaction (ChIP-qPCR) is the final protocol in the pipeline and evaluates DNA-protein interactions at specific regions of the genome. In this assay, genomic regions enriched in H3K27ac are purified through immunoprecipitation (IP) and analyzed using DNA primers in qPCR. This technique provides mechanistic insight into how HATi affects histone modifications at gene promoters and enhancers. ChIP-qPCR is a robust technique and is less costly than whole-genome sequencing (e.g., ChIP-seq), but it can be difficult to optimize due to many steps that affect the outcome. The most difficult step to correctly optimize is step 3.5, the immunoprecipitation. This step is difficult to optimize because if the purified DNA in step 3.5.20 is highly dilute it can cause poor results in the qPCR reaction (e.g., no amplification of the target gene sequence and very high ΔCt values). The success of the IP step is dependent on several factors, such as the abundance of the protein target of interest and the quality of the IP antibody. It is crucial to validate the quality of the IP H3K27ac antibody versus the IgG control to verify the success of the IP step. For example, in Figure 3B, the H3K27ac specific antibody displays 632.73-fold enrichment over the non-specific IgG control. This indicates that the H3K27ac antibody is high quality and that H3K27ac is enriched at the Cyclin D1 promoter. After validation of the IP antibody, a comparison can be made between the DMSO and A-485 treated groups. As shown in Figure 3C, A-485 reduces H3K27ac enrichment at the Cyclin D1 promoter versus the DMSO control using the %Input method (representative result of n=2). If the IP antibody proves to be low quality and does not show fold enrichment in initial experiments, try increasing the cell numbers in step 3.2.1. Higher cell numbers can help compensate for poor antibody quality by increasing the total protein content of the lysate and will allow more protein to be added to the IP reaction.
The authors have nothing to disclose.
This work was supported by grants from James and Esther King Biomedical Research Program (6JK03 and 20K07), and Bankhead-Coley Cancer Research Program (4BF02 and 6BC03), Florida Department of Health, Florida Breast Cancer Foundation, and UF Health Cancer Center. Additionally, we would like to thank Dr. Zachary Osking and Dr. Andrea Lin for their support during the publication process.
1.5 ml tube | Fisher Scientific | 05-408-129 | For all methods |
10 cm dish | Sarstedt AG & Co. | 83.3902 | For cell culture of MCF-7 cells |
10 ul tips | Fisher Scientific | 02-707-454 | For all Methods |
1000 ul tips | Corning | 4846 | For all Methods |
10X Glycine buffer | For Method 3. See Table 1 for recipe. | ||
10X Running Buffer | For Methods 1 and 2. See Table 1 for recipe. | ||
10X TBST | For Methods 1 and 2. See Table 1 for recipe. | ||
12 well plate | Corning | 3513 | For Method 2 |
15 cm dish | Sarstedt AG & Co. | 83.3903 | For Method 3 |
15 ml conical tube | Santa Cruz Biotechnology | sc-200249 | For Methods 2 and 3 |
1X TBST with 5% milk and 0.02% Sodium Azide | For Methods 1 and 2. Can be used to dilute primary antibodies that will be used more than once. Allows for short-term storage of primary antibody dilutions. Do not use for secondary antibody diluton. CAUTION: Sodium Azide is toxic. | ||
1X TBST with 5% milk | For Methods 1 and 2. Used to block PVDF membrane and for antibody diltions. See Table 1 for recipe. | ||
200 ul tips | Corning | 4844 | For all Methods |
2-mercaptoethanol | Sigma-Aldrich | M3148 | for SDS sample buffer preparation |
4-20% polyacrylamide gel | Thermo Fisher: Invitrogen | XP04205BOX | For Methods 1 and 2 |
5X Assay buffer | For Method 1. See Table 1 for recipe. | ||
5X Passive lysis buffer | For Method 2. See Table 1 for recipe. | ||
6X Sodium Dodecyl Sulfate (SDS) | For Methods 1 and 2. See Table 1 for recipe. | ||
A-485 | MedChemExpress | HY-107455 | CBP/p300 Inhbitor for use in Methods 2 and 3. Dissolved in DMSO. |
Acetyl-CBP(K1535)/p300(K1499) antibody | Cell Signaling Technology | 4771 | For Method 1 |
Acetyl-CoA | Sigma-Aldrich | A2056 | for use in Method 1 |
Acetyl-Histone H3 (Lys 27) antibody (H3K27ac) | Cell Signaling Technology | CST 8173 | antoibodies for H3K27ac for immunoblots and ChIP |
Acetyl-Histone H3 (Lys18) antibody (H3K18ac) | Cell Signaling Technology | CST 9675 | antoibodies for H3K18ac for immunoblots and ChIP |
alpha tubulin antibody | Millipore Sigma | T5168 | For Method 2. Dilute 1:20,000 |
Anacardic acid | Cayman Chemical | 13144 | For Method 1 |
anti-mouse IgG HRP linked secondary antibody | Cell Signaling Technology | 7076 | For Methods 1 and 2. Dilute 1:10,000 |
anti-rabbit IgG secondary antibody | Jackson ImmunoResearch | 711-035-152 | For Methods 1 and 2. Dilute 1:10,000 to 1:20,000 |
Autoradiography film | MIDSCI | BX810 | For Methods 1 and 2 |
Belly Dancer Rotating Platform | Stovall Life Science Incorporated | not available | For Methods 1 and 2 |
Bovine Calf Serum (BCS) | HyClone | SH30072.03 | cell culture media |
Bovine Serum Albumin (BSA) | Sigma-Aldrich | A2153 | for buffer preparation |
Bromophenol Blue | Sigma-Aldrich | B0126 | for SDS sample buffer preparation |
CDTA | Spectrum Chemical | 125572-95-4 | For buffer preparation |
cell scraper | Millipore Sigma | CLS3010 | For Method 3 |
ChIP dilution buffer | For Method 3. See Table 1 for recipe. | ||
ChIP Elution Buffer | For Method 3. See Table 1 for recipe. | ||
Complete DMEM for MCF-7 Cells | For Methods 2 and 3. See Table 1 for recipe. | ||
Covaris 130 µl microTUBE | Covaris | 520045 | Sonication tube for use with Covaris S220 in Method 3 |
Covaris S220 Focused-ultrasonicator | Covaris | S220 | DNA sonicator for use in Method 3 |
Dimethyl sulfoxide (DMSO) | Sigma-Aldrich | 41639 | for drug dilution and vehicle control treatment |
DL-Dithiothreitol (DTT) | Sigma-Aldrich | 43815 | for SDS sample buffer preparation |
DMEM | Corning | 10-013-CV | cell culture media |
EDTA | Fisher Scientific | BP120-1 | for buffer preparation |
Example transfer tank and transfer apparatus | Bio-rad | 1704070 | For Methods 1 and 2 |
EZ-Magna ChIP A/G Chromatin Immunoprecipitation Kit | Millipore Sigma | 17-10086 | For Method 3 |
FK228 (Romidepsin) | Cayman Chemical | 128517-07-7 | HDAC Inhibitor for use in Method 2 |
Formaldehyde solution | Sigma-Aldrich | F8775 | for cell fixation |
glycerol | Fisher Scientific | BP229-1 | For buffer preparation |
glycine | Sigma-Aldrich | G7126 | for buffer preparation |
HEPES | Sigma-Aldrich | 54457 | for buffer preparation |
High salt wash buffer | For Method 3 | ||
IGEPAL (NP-40) | Sigma-Aldrich | I3021 | for buffer preparation |
Immobilon Chemiluminescent HRP Substrate | Millipore Sigma | WBKLS0500 | For Methods 1 and 2 |
KCl | Fisher Scientific | BP366-500 | for buffer preparation |
LiCl | Sigma-Aldrich | L9650 | For buffer preparation |
LiCl wash buffer | For Method 3. See Table 1 for recipe. | ||
Low salt wash buffer | For Method 3. See Table 1 for recipe. | ||
Magnetic Separator | Promega | Z5341 | For use in Method 3 |
Methanol | Sigma-Aldrich | 494437 | For buffer preparation |
Mini gel tank | Invitrogen | A25977 | For Methods 1 and 2 |
MS-275 (Entinostat) | Cayman Chemical | 209783-80-2 | HDAC Inhibitor for use in Method 2. Dissolved in DMSO. |
NaCl | Fisher Scientific | 7647-14-5 | for buffer preparation |
NaOH | Fisher Scientific | S318-100 | for buffer preparation in Methods 1 and 2 |
Normal Rabbit IgG | Bethyl Laboratories | P120-101 | Control rabbit antibody for use in Method 3 |
Nuclei swelling buffer | For Method 3. See Table 1 for recipe. | ||
PCR Cleanup Kit | Qiagen | 28104 | For use in Method 3 |
Penicillin/Streptomycin 100X | Corning | 30-002-CI | cell culture media |
Phosphate-buffered saline (PBS) | Corning | 21-040-CV | For Methods 2 and 3 |
PIPES | Sigma-Aldrich | 80635 | for buffer preparation |
powdered milk | Nestle Carnation | For Methods 1 and 2 | |
Power Pac 200 for western blot transfer | Bio-rad | For Methods 1 and 2 | |
Power Pac 3000 for SDS gel running | Bio-rad | For Methods 1 and 2 | |
Prestained Protein Ladder | Thermo Fisher | 26616 | For Methods 1 and 2 |
Protease Inhibitor Cocktail | Sigma-Aldrich | PI8340 | for use in Method 3 |
Protein A Magentic Beads | New England BioLabs | S1425S | For use in Method 3 |
Proteinase K | New England BioLabs | P8107S | For use in Method 3 |
PTC-100 Programmable Thermal Controller | MJ Research Inc. | PTC-100 | For Method 1 |
PVDF Transfer Membrane | Millipore Sigma | IEVH00005 | For Methods 1 and 2 |
Recombinant H3.1 | New England BioLabs | M2503S | for use in Method 1 |
Recombinant p300 | ENZO Life Sciences | BML-SE451-0100 | for use in Method 1 |
SAHA (Vorinostat) | Cayman Chemical | 149647-78-9 | HDAC Inhibitor for use in Method 2 |
SDS lysis buffer | For Method 3. See Table 1 for recipe. | ||
Sodium Azide | Fisher Scientific | 26628-22-8 | For Methods 1 and 2. CAUTION: Sodium Azide is toxic. See SDS for proper handling. |
Sodium Bicarbonate | Fisher Scientific | S233-500 | for buffer preparation |
Sodium deoxycholate | Sigma-Aldrich | D6750 | for buffer preparation |
Sodium dodecyl sulfate (SDS) | Sigma-Aldrich | 71725 | for SDS sample buffer preparation |
Standard Heatblock | VWR Scientific Products | MPN: 949030 | For Methods 1 and 2 |
Table top centrifuge | Eppendorf | 5417R | For all methods |
TE buffer | For Method 3. See Table 1 for recipe. | ||
Transfer buffer | For Methods 1 and 2. See Table 1 for recipe. | ||
Trichostatin A | Cayman Chemical | 58880-19-6 | HDAC Inhibitor for use in Method 2 |
Tris | Fisher Scientific | BP152-5 | for buffer preparation |
Triton X-100 | Sigma-Aldrich | T8787 | for buffer preparation |
Tween 20 | Sigma-Aldrich | 9005-64-5 | for buffer preparation in Methods 1 and 2 |
X-ray film processor | Konica Minolta Medical & Graphic, Inc. | SRX-101A | For Methods 1 and 2 |